The metabolic consequences of the NADP + -dependent isocitrate dehydrogenase (IDH) 1 mutation was studied quantitatively in glioblastoma, the most aggressive form of brain tumor. The mutation is found in 70-80% of secondary glioblastoma. Metabolic rewiring of cells due to the mutation causes gliomagenesis by the production of 2-hydroxyglutarate. On the other hand, glioblastoma patients with the IDH1 mutation have a significant survival benefit of approx. one year. We found that the NADPH production capacity in glioblastoma is reduced by 38% when IDH1 is mutated [1] . We hypothesized that this reduced production capacity of NADPH, a major metabolite involved in detoxification processes, renders glioblastoma cells less resistant against irradiation and chemotherapy and thus prolong patient survival [2] . We also demonstrated that cellular metabolism is rewired in IDH1-mutated glioblastoma cells by elevated mitochondrial activity [3] . Further metabolic studies of human and rodent tissues showed that IDH activity is responsible for 65% of the NADPH production capacity in human brain and only for 15% in rodent brain whereas the pentose phosphate pathway was responsible for 85% of the NADPH production capacity in rodent tissues [4] . It explains why the pentose phosphate pathway was always linked with cancer and not IDH because most studies on metabolism and cancer have been performed in rodents.
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In conclusion, our metabolic study strongly suggests that the reduced NADPH production capacity in IDH1-mutated gliomablastoma makes cancer cells less resistant and as a consequence is at least partly responsible for prolonged patient survival.
